Expertise in
6
conditions

Dr. Ronald N. Levy

Oncology
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 
Expertise in
6
conditions
Stanford Hospital And Clinics
965 High St, 
Palo Alto, CA 

Overview

Ronald Levy is an Oncologist practicing medicine in Palo Alto, California.

Dr. Levy is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), and B-Cell Lymphoma.

He is actively involved in clinical research, co-authoring 95 peer reviewed articles and participating in 6 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO

Locations

Stanford Hospital and Clinics
965 High St, Palo Alto, CA 94301
Other Locations
Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
The Seena Magowitz Phase IB/II Trial of CMP-001 (a TLR9 Agonist) in Combination With INCAGN01949 (an Activating Anti-OX40 Antibody) for In Situ Intratumoral Injection for Patients With Stage IV Pancreatic and Other Cancers Except Melanoma
Enrollment Status: Terminated
Publish Date: April 17, 2026
Intervention Type: Biological, Drug
Study Drugs: Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
Study Phase: Phase 1/Phase 2
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug, Biological, Other, Radiation
Study Drugs: Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101
Study Phase: Phase 1
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: Ibrutinib, TLR9 Agonist SD-101
Study Phase: Phase 1/Phase 2
Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for Mantle Cell Lymphoma
Phase 1-2 Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: January 13, 2020
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas
A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas
Enrollment Status: Completed
Publish Date: November 27, 2019
Intervention Type: Biological, Radiation, Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas
Enrollment Status: Terminated
Publish Date: September 25, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

95 Total Publications

Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell Lymphoma.
Personalized Neoantigen Vaccines Synergize with Immune Checkpoint Therapy and CD8-Targeted Cytokines to Control B-Cell Lymphoma.
Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Stanford University

875 Blake Wilbur Dr, 
Palo Alto, CA 
 (1.1 miles away)
650-498-6000
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist practicing medicine in Palo Alto, California. She has been practicing medicine for over 44 years. Dr. Advani is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and Tissue Biopsy.

Expertise in
33
conditions
Expertise in
33
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kristen Ganjoo is an Oncologist practicing medicine in Palo Alto, California. Dr. Ganjoo is highly rated in 33 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (0.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joel Neal is an Oncologist practicing medicine in Palo Alto, California. Dr. Neal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Thymic Epithelial Tumor, and Tissue Biopsy.

Frequently Asked Questions about Dr. Ronald N. Levy

How do I make an appointment with Dr. Ronald N. Levy?

You can book an appointment with Dr. Ronald N. Levy by calling their office at 650-723-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronald N. Levy a top-rated expert for Follicular Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronald N. Levy is classified as an Elite expert for Follicular Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronald N. Levy specialize in?

While Dr. Ronald N. Levy is a Oncology, they have specific expertise in Follicular Lymphoma, Non-Hodgkin Lymphoma, and Mantle Cell Lymphoma (MCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Ronald N. Levy participate in research or clinical trials?

Yes. Dr. Ronald N. Levy has published 95 articles and abstracts on conditions like Follicular Lymphoma. You can view a list of Dr. Ronald N. Levy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ronald N. Levy accept my insurance?

Dr. Ronald N. Levy accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 650-723-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levy's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile